Valrubicin - @ - Antracyclines - Antibiotics
Drug Name:
Valrubicin - @ - Antracyclines - Antibiotics
List Of Brands:
Indication Type Description:
Indication:
Bacillus Calmette- Guerin -refractory carcinoma in situ
Adverse Reaction:
Adverse Reactions-
Any local bladder pain 40%
Bladder pain 5%
Dysuria 10%
Hematuria 10%
Urinary frequency 25%
Urinary urgency 20%
Contra-Indications:
Known hypersensitivity to the components
Special Precautions/Warnings
Compromised bladder - evaluate the state of the bladder before the intravesical installation of the drug
Antiseptic technique- antiseptic technique must be used during administration of intrvesical valrubicin to avoid introducing contaminants into the urinary tract.
Irritable bladder symptoms- use valrubicin with caution in patients with severe bladder syndrome
Pregnancy- valrubicin may cause fetal harm to a pregnant woman.
Lactation- Women should discontinue breast feedng before initiation of therapy
Children- safety and efficacy in children not established
Dosages/ Overdosage Etc:
Indication-
Bacillus Calmette- Guerin -refractory carcinoma in situ
Dosage-
800mg adminstered intravesically once a week for 6 weeks.
Adminstration should be delayed at least 2 weeks after transurethal resection and or fuulgration
Storage - unopened vial are stable until the date indicated on the package.
Store under refrigerated conditions at 2 to 8C ( 36 to 46F ). Store incartons
Do not freeze
Patient Information:
1.Inform patients that major toxicities are related to irritable syndrome that can occur during
instillation, and retention of valrubicin and for limited period following voiding. . For the
first 24 hours following administration red tinge urine is typical
2. Inform patients to report prolonged irritable bladder syndrome or prolonged passage of
red colored urine, to their doctor.
3. Advice women of child bearing potential not to become pregn during treatment
4. Advice men to refrain from procreative activites while receiving therapy.
5. Advice all patients of reproductive age to use an effective contraception method during
the treatment period
Pregnancy and lactation:
Pregnancy-
Valrubicin may cause fetal harm to a pregnant woman.
Lactation-
Women should discontue breast feedng before initiation of therapy
Children -
Safety and efficacy in children not established
